Literature DB >> 15671248

Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaB-dependent cancer cell survival.

Shelby O'Connor1, Stuart Shumway, Shigeki Miyamoto.   

Abstract

Deregulation of the transcription factor nuclear factor-kappaB (NF-kappaB) leading to its constitutive activation is frequently observed in human cancer. Because altered NF-kappaB activities often promote the survival of malignant cells, its inhibition is regarded as a promising anticancer strategy. Because activation of the latent cytoplasmic NF-kappaB complex can be induced by a wide variety of different stimuli, its deregulation may occur by an equally large number of distinct mechanisms. This diversity raises a conundrum in conceptualizing general approaches to attenuate NF-kappaB activity in cancer. Here, we provide evidence that inhibition of IkappaBalpha nuclear export is a viable target to generally abrogate constitutive NF-kappaB activity in different cancer cell types. We show that inhibition of IkappaBalpha nuclear export has an important course of events in cancer cells harboring constitutive NF-kappaB activity-an initial increase in the pool of stable nuclear NF-kappaB/IkappaBalpha complexes that leads to a reduction of constitutive NF-kappaB activity and subsequent induction of apoptosis. Importantly, similar effects on multiple different cancer cell types indicate that inhibition of nuclear export of IkappaBalpha leads to broad inhibition of constitutive NF-kappaB activation regardless of various deregulated, upstream events involved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671248

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

1.  Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.

Authors:  Hai-Yen Vu; Ashish Juvekar; Chandra Ghosh; Sitharam Ramaswami; Dung Hong Le; Ivana Vancurova
Journal:  Arch Biochem Biophys       Date:  2008-04-29       Impact factor: 4.013

2.  Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation.

Authors:  Shelly M Wuerzberger-Davis; Yuhong Chen; David T Yang; Jeffrey D Kearns; Paul W Bates; Candace Lynch; Nicholas C Ladell; Mei Yu; Andrew Podd; Hu Zeng; Tony T Huang; Renren Wen; Alexander Hoffmann; Demin Wang; Shigeki Miyamoto
Journal:  Immunity       Date:  2011-02-17       Impact factor: 31.745

3.  Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.

Authors:  Olivia Perwitasari; Scott Johnson; Xiuzhen Yan; Elizabeth Howerth; Sharon Shacham; Yosef Landesman; Erkan Baloglu; Dilara McCauley; Sharon Tamir; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

4.  Potential effects of CRM1 inhibition in mantle cell lymphoma.

Authors:  Ke-Jie Zhang; Michael Wang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

5.  TRAF6 maintains mammary stem cells and promotes pregnancy-induced mammary epithelial cell expansion.

Authors:  Mizuki Yamamoto; Chiho Abe; Sakura Wakinaga; Kota Sakane; Yo Yumiketa; Yuu Taguchi; Takayuki Matsumura; Kosuke Ishikawa; Jiro Fujimoto; Kentaro Semba; Maki Miyauchi; Taishin Akiyama; Jun-Ichiro Inoue
Journal:  Commun Biol       Date:  2019-08-06

6.  Tip110/SART3-Mediated Regulation of NF-κB Activity by Targeting IκBα Stability Through USP15.

Authors:  Khalid Amine Timani; Sahar Rezaei; Amanda Whitmill; Ying Liu; Johnny J He
Journal:  Front Oncol       Date:  2022-04-21       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.